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Background: The goal of this study was to identify the clinicopathological factors of co-existing papillary thyroid
cancer (PTC) in patients with Hashimoto’s thyroiditis (HT) and provide information to aid in the diagnosis of such
patients.
Methods: This study included 6109 patients treated in a university-based tertiary care cancer hospital over a 3-year
period. All of the patients were categorised based on their final diagnosis. Several clinicopathological factors, such
as age, gender, nodular size, invasive status, central compartment lymph node metastasis (CLNM) and serum
thyroid-stimulating hormone (TSH) level, were compared between the various groups of patients.
Results: There were 653 patients with a final diagnosis of HT. More PTC was found in those with HT (58.3%; 381 of
653) than those without HT (2416 of 5456; 44.3%; p < 0.05). The HT patients with co-occurring PTC were more likely
to be younger, be female, have smaller nodules and have higher TSH levels than those without PTC. A multivariate
analysis indicated that the presence of HT and higher TSH levels were risk factors for a diagnosis of PTC. In the PTC
patients, the presence of HT or another benign nodule was a protective factor for CLNM, whereas no significant
association was found for TSH levels.
Conclusion: PTC and HT have a close relationship in this region of highly prevalent HT disease. Based on the
results of our study, we hypothesise that long-term HT leads to elevated serum TSH, which is the real risk factor for
thyroid cancer.
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Thyroid cancer is the most common endocrine carcin-
oma, and papillary thyroid carcinoma (PTC) is the 7th
most common cancer among women in the world [1].
There are numerous risk factors for PTC, including
radiation exposure, insufficient iodine intake, hormonal
factors, and family history [2]. It is noteworthy that mo-
lecular analyses have indicated that lymphocytic infiltra-
tion is frequently observed in PTC, suggesting that
immunological factors might be involved in tumour* Correspondence: jiqinghai@shca.org.cn
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reproduction in any medium, provided the orprogression [3,4]. Hashimoto’s thyroiditis (HT) is the
most common inflammatory thyroid disease and the
most common cause of hypothyroidism in the United
States, affecting 22 of every 100,000 individuals. In
China, the rates are even higher, with approximately
0.4-1.5% of the population affected, which accounts for
20-25% of the thyroid disease cases in this country [5-7].
Since Dailey et al. first proposed a relationship be-
tween HT and PTC in 1955 [8], there have been many
reports on this topic, with conflicting conclusions. Cer-
tain authors have agreed that there may be a positive
correlation between HT and PTC [8-14], whereas others
have not [15-19].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ship between HT and PTC using a large population sam-
ple from an area with a high HT prevalence.Results
Clinical characteristics
In total, 6109 patients underwent thyroid surgery in our
hospital during the study period (538 males and 4571
females); 3288 of these patients had a final diagnosis of
benign thyroid nodule, and 2821 had a final diagnosis of
PTC. The ages of the patients ranged from 8 to 88 years
of age (mean, 46.1±12.3 years of age). There were 653
patients with HT in our study population. Age, female
gender, and nodule size were significantly different be-
tween the patients with and without HT. The basic char-
acteristics of the patients are shown in Table 1. Of the
6109 patients, 5115 patients had had their preoperative
serum thyroid-stimulating hormone (TSH) and free thy-
roxine (T4) concentrations measured within the 2 weeks
before their surgery and were included in the TSH ana-
lysis. Due to the unavailability of their preoperative thy-
roid function, 994 patients were excluded from the TSH
analysis. Among these patients, 260 were prescribed
levothyroxine (LT4) preoperatively, and the remainder
did not have a serum thyroid function test within the 2
weeks prior to their surgery. The 994 patients included
25 patients with HT (23 cases with co-occurring PTC
and 2 with benign disease) and 969 patients without HT
(178 patients with PTC and 791 with benign disease).
All the 5115 patients fulfilled the following criteria: 1)
They were not taking L-T4 or methimazole and were
not overtly hyperthyroid or hypothyroid. 2) They had
TSH, free thyroid hormones and thyroidglobulin anti-
bodies measured within one week prior to thyroidec-
tomy. 3) They had not undergone any type of previous
thyroid surgery.
We then analysed the serum TSH levels of the 5115
patients in the TSH analysis to determine the association







Number of patients 653 5456
Age (years) 44.4±11.9 46.3±12.3 0.077
Gender
Male 56 1482 0.001
Female 597 3974
Nodule Size (cm) 1.75±1.23 2.26±1.48 0.001
PTC 381(58.3%) 2440(44.3%) 0.001
PTC cancer with serum
TSH
358(54.8%) 2262(41.6%) 0.001Comparison of the clinicopathological factors between
patients with and without HT
In the first phase of the study, we compared the clinico-
pathological factors of the patients with and without
HT. A total of 628 patients with HT and 4487 patients
without HT had a serum TSH examination before their
surgery. In comparing the patients with and without HT,
it was found that gender (female), age, nodule size and
serum TSH levels were significant indicators of a positive
HT diagnosis. Subsequently, the following factors were
compared between the 2 sub-groups: 1) if the patients
with HT suffered from PTC; and 2) if the patients with
benign disease suffered from HT. The results show that
in the patients with HT, both with and without PTC, the
patient’s age, nodule size and serum TSH level still were
significant indicators of a positive HT diagnosis (made a
difference), whereas the gender (female) was not. In the
patients with benign disease, both with and without HT,
the patient’s gender (female), age, nodule size and serum
TSH level also were significant indicators of a positive
diagnosis (Table 2).Comparison of the clinicopathological factors among
patients with PTC
In the second phase of the study, we examined the clini-
copathological factors, including HT, in the patients with
PTC. Among the patients with PTC, both with and with-
out HT, it was found that gender (female), nodule size,
central compartment lymph node metastasis (CLNM)
and serum TSH level had a significant difference. Fur-
thermore, we compared the patients with both PTC and
HT with the patients with PTC only and the patients
with PTC and co-occurring benign diseases. The results
show that age, gender (female), CLNM and serum TSH
level all differed in the two comparisons. The nodule size
only differed in the comparison between the patients
suffering from PTC with HT and patients suffering from
PTC with benign diseases. The invasion of a primary
tumour only differed in the comparison between the
patients with PTC and co-occurring HT and patients
with PTC only (Table 3).
Independent risk factors for PTC
After the two phases discussed above, the clinicopatho-
logical factors were examined in univariate and multi-
variate analyses to assess the PTC risk factors in all 5115
patients. In the univariate analysis, it was found that age
(>45 years of age) and nodule size (>1 cm) had signifi-
cant odds ratios (ORs) less than 1, whereas HT and
serum TSH had significant ORs greater than 1. In the
multivariate analysis, these four factors were also signifi-
cant. Interestingly, the HT had an OR of less than 1 after
the multivariate analysis (Table 4).
Table 2 Comparison of the clinicopathological factors in patients with or without HT
Total patients (5115) Patients with HT (628) Patients with Benign disease(2495)




















358(57.00%) 270(43.00%) 270 2225
Age (years) 44.35
±11.99
46.28±12.27 0.001 42.64±12.04 46.62±11.56 0.001 46.62±11.56 48.38±12.35 0.018
Female 573 3248 0.001 330 243 0.339 243 1608 0.001
Nodule size (cm) 1.81±1.23 2.32±1.50 0.001 1.21±0.90 2.44±1.32 0.001 2.64±1.32 3.33±1.34 0.001
TSH 2.82±2.38 2.22±1.90 0.001 3.26±2.54 2.23±2.02 0.001 2.23±2.02 1.91±2.03 0.025
*:All the patients in the table had serum TSH test.
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metastasis
Because prophylactic central lymph node dissection
(CLND) was routinely performed for PTC patients at
our hospital, univariate and multivariate analyses of the
CLNM were also performed. The results of the univa-
riate analysis showed that PTC patients with HT and
PTC patients with benign disease had a significant OR
of less than 1, whereas nodule size (>1 cm), serum TSH
level and invasion by the primary tumour had significant
ORs greater than 1. In the multivariate analysis, the PTC
patients with HT and PTC patients with benign disease
also showed a protective effect, whereas only nodule size
(>1 cm) and invasion by the primary tumour were asso-
ciated with increased risk (Table 5).
Histomorphological features of HT and PTC
Based on all of the pathological results of the patients in
our study population, four typical figures were chosen to
show the histomorphological features of HT only, PTC
only and HT co-existence with PTC. Additional file 1:
Figure S1 shows the histomorphological features of HT,
which consisted of the typical germinal centres of HT.
Additional file 1: Figure S2 and Figure S3 show the his-
tomorphological features of HT co-existence with PTC.
These two figures show the close histomorphologicalTable 3 Comparison of the clinicopathological factors in PTC
PTC with HT PTC without HT P value PTC with
Number of patients 358(13.67%) 2262(86.34%) 358(13.67
Age (years) 42.64±12.04 44.21±11.83 0.058 42.64±12
Female 350 1640 0.001 350
Nodule size (cm) 1.21±0.90 1.33±0.81 0.001 1.21±0.9
Invasion 69 506 0.250 69
Level VI 153 1358 0.001 153
Lateral& 37 349 0.133 37
TSH 3.26±2.54 2.53±1.72 0.001 3.26±2.5
* total number of PTC patients with TSH : 2620.
&:Lateral neck metastasis &.relationship between HT and PTC. Additional file 1:
Figure S4 shows the typical histomorphological features
of PTC.
Discussion
Both HT and PTC have a high prevalence worldwide,
and these conditions may have a close relationship.
Thus, there may be many patients who have both dis-
eases simultaneously. Whether PTC represents a reactive
response to HT or HT is a prerequisite tumourigenic
event still remains to be determined.
In our population, 653 patients suffered from HT du-
ring the period from 2008 to 2010. Of these patients,
58.3% had co-occurring PTC, which was a higher rate
than in previous reports [8-19]. If the patients were sub-
divided by gender, the result was statistically significant
for the females with HT. Compared with the females
without HT, the women with HT were found to be ap-
proximately 30% more likely to have co-occurring PTC.
Our findings in this patient population support the pre-
vious studies linking HT with PTC [10,13,20].
At the molecular level, the evidence shows that HT may
be a precursor of PTC. It is well known that RET was the
first activated receptor-tyrosine kinase to be identified
in papillary thyroid cancer. The proto-oncogene, located
on chromosome 10q11.2, encodes a transmembranepatients with TSH
HT PTC only P value PTC with HT PTC with Benign P value
%) 1270(48.47%) 358(13.67%) 992(37.86%)
.04 44.29±11.73 0.020 42.64±12.04 44.12±11.95 0.023
925 0.000 350 715 0.001
0 1.23±0.78 0.845 1.21±0.90 1.45±0.84 0.001
342 0.003 69 164 0.178
827 0.001 153 531 0.001
216 0.635 37 133 0.427
4 2.45±1.59 0.001 3.26±2.54 2.63±1.86 0.001
Table 4 Independent risk factors for papillary thyroid cancer, as identified by the univariate and multivariate logistic
regression analyses
Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Gender (Male vs. Female) 1.054 (0.930-1.196) 0.410 0.927 (0.796-1.080) 0.329
Age (≤45years vs. >45 years) 0.520 (0.465-0.581) 0.001 0.505 (0.442-0.576) 0.001
HT (HT vs. no HT) 1.304 (1.102-1.544) 0.002 0.859 (0.724-0.998) 0.001
Nodule size (>1 cm vs. ≤1 cm) 0.010 (0.006-0.016) 0.001 0.009 (0.005-0.014) 0.001
TSH (constant) 1.303 (1.254-1.355) 0.001 1.361 (1.304-1.421) 0.001
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in the extracellular domain [21]. The reported overall
prevalence of RET/PTC rearrangements in papillary car-
cinomas varies from 3% to as high as 85%, depending on
the detection methods and geographical location of the
patients; a reasonable range is 13–43% [22-27]. More-
over, RET/PTC rearrangements have also been reported
in the thyroids of patients with the autoimmune inflam-
matory condition known as Hashimoto’s thyroiditis
[28-31]. However, these findings are controversial and
might reflect either PCR contamination or the presence
of microscopic nodules of papillary carcinoma, as stu-
dies that have excluded these possibilities do not confirm
the data [32,33]. Whether RET/PTC rearrangements in-
duce HT to PTC remains unknown. The connection of
RET/PTC rearrangements in HT and PTC requires fur-
ther investigation.
However, several retrospective and prospective studies
have found no correlation between these two diseases.
Interestingly, our univariate analysis found that HT is a
risk factor for PTC, whereas HT played a protective role
in the multivariate analysis, which is consistent with pre-
vious reports. It is difficult to explain this phenomenon.
It has been hypothesised that serum TSH levels may
play an important role. Since Boalart et al. found that
elevated serum TSH can be a risk factor for PTC [34],
many studies have replicated their results [15,35-41].
Thus, when considering whether HT is a risk factor for
PTC, it is important to evaluate the serum TSH level. In
our study, most of the patients’ serum TSH levels were
evaluated before their surgeries. As Table 2 and Table 3
show, the HT patients had higher TSH levels than theTable 5 Independent risk factors for central lymph node met
and multivariate logistic regression analyses
Unadjusted OR (95% CI)
Gender (Male vs. Female) 0.865 (0.722-1.037)
Age (≤45years vs. >45 years) 1.079 (0.923-1.261)
HT (HT vs. no HT) 0.497 (0.396-0.623)
Nodule Size (>1 cm vs. ≤1 cm) 2.507 (2.138-2.941)
TSH (constant) 1.303 (1.254-1.355)
With benign (with vs. without) 0.814 (0.696-0.952)
Invasion (yes vs. no) 9.804 (7.346-13.084)patients without HT. Moreover, the patients with co-
occurring HT and PTC had the highest serum TSH
levels among all of the sub-groups.
It is well known that serum TSH has a trophic effect
on follicular-cell-derived thyroid cancer growth. Unfor-
tunately, the present study could not provide evidence
concerning the malignant transformation of thyroid fol-
licular cells in the TSH-cAMP pathway. Recently,
genome-wide association studies (GWAS) and carefully
designed candidate gene approaches have determined
that the FOXE1 genetic variant, which is downstream of
the TSH-cAMP pathway, is the suspected risk factor for
follicular-cell-derived thyroid cancer [42-44]. In the fu-
ture, genetic studies may provide stronger evidence sup-
porting the theory that high TSH levels cause thyroid
cancer. When considering HT, it should be recognised
that long-term HT can cause hypothyroidism, which ele-
vates the serum TSH level. In China, where iodine in-
take is increasing, there is a high prevalence of HT and
hypothyroidism in subjects with euthyroidism [7]. In our
study, the rates of co-occurring PTC in the HT patients
were higher than those in previous reports [8-19]. Con-
sidering these results, we hypothesise that long-term HT
causes elevated serum TSH, which is the real thyroid
cancer risk factor. This hypothesis may explain why HT
was a risk factor in the univariate analysis, whereas in
the multivariate analysis, which controlled for TSH
levels, HT became a protective factor. Furthermore, this
hypothesis may explain why several of the prospective
studies that have examined the association between HT
and thyroid cancer have found negative results (i.e., be-
cause the HT patients in these studies did not have highastatic papillary thyroid cancer, as identified by univariate
P value Adjusted OR (95% CI) P value
0.117 0.932 (0.763-1.139) 0.493
0.341 1.110 (0.933-1.319) 0.239
0.001 0.450 (0.347-0.583) 0.001
0.001 2.332 (1.944-2.797) 0.001
0.001 1.008 (0.962-1.057) 0.727
0.001 0.670 (0.559-0.802) 0.001
0.001 10.092 (7.382-13.797) 0.001
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growth factor for PTC, the serum TSH could be an indi-
vidual marker for each HT patient. In clinic, doctors
could control the serum TSH level under a lower level
in the normal range of TSH for HT patients [45].
With regard to the clinical course, thyroid tumours
associated with HT do not appear to be any more ag-
gressive than those not associated with HT [20,46]. In
our series of studies, we found that PTC patients with
HT had less aggressive tumours than the patients with
PTC only. Interestingly, the PTC patients with HT had
less CLNM than those without HT (Table 3). This result
conflicts with those of a previous report [14]. In Table 5,
TSH is not a factor associated with an increased risk of
central lymph node metastases in patients with PTC,
which is not in agreement with Kim’s study [47]. The
Kim’s study included only 554 patients, which was less
than our patients. This might cause our different result.
Furthermore, we take TSH as a constants variable,
while Kim’s study considered TSH as a dichotomous
variable.
Recently, Hanahan et al. proposed a new hallmark of
cancer genesis: “Tumor-Promoting Inflammation.” [48]
This new hallmark could play an important role in the
pathogenic process of co-occurring PTC and HT. In cer-
tain cases, it is evident that inflammation is present at
the earliest stages of neoplastic progression and capable
of fostering the development of incipient neoplasia into
cancer and causing the invasion and metastasis of exist-
ing cancer [49,50]. It is certain that in the near future,
the relationship between inflammation and cancer inva-
sion or metastasis will be further elucidated.
Consistent with previous reports [14,15], our study
also found that a nodule >1 cm plays a protective role in
our study population (Table 4). This finding may have
been due to the selection of patients for surgery. Patients
with the small benign nodules are typically not sent to
surgery, whereas patients with larger benign nodules, es-
pecially >4 cm, are more likely to be candidates for sur-
gical treatment. However, in PTC patients, a primary
tumour > 1 cm is a risk factor for neck metastasis
(Table 5). Also, there was an interesting phenomenon
that the cancer size of “PTC with benign disease” is lar-
ger than “PTC only” or “ PTC with HT”, while “PTC
with benign diseas” shows less or similar invasion. This
might be due to the different genetic origin of different
types of PTC. The genesis of "PTC with benign nodule"
might come from the benign nodule, which is less inva-
sion [51]. The genesis of “PTC only” might come from
the somatic mutation, which is more invasion.
In the morphological examination, an extensive rela-
tionship was shown between HT and PTC (Additional
file 1: Figure S1-S4). Thus, based on the histomorpholo-
gical features, laboratory findings and clinical data, theco-occurrence of PTC and HT is an interesting topic con-
cerning thyroid cancer research and cancer hallmarks.
We also have some limitations in this study. Since our
study is a retrospective cross-section study, there could
be a selection bias in the incidence of PTC in HT. The
number of HT patients who develop nodules was not
given. Next, we could not estimate the mean time for
the HT patient who would suffer from PTC. It is neces-
sary that the basic research on raised TSH causing PTC
in HT patients should be done in the future, which
could provide more powerful evidence for the correl-
ation of HT and PTC.
Conclusion
PTC and HT have a close relationship in an area with a
high prevalence of HT disease. Based on the results of
our study, we hypothesise that long-term HT could
cause elevated serum TSH, which is the real risk factor
for the development of thyroid cancer. Furthermore, the
disease’s invasiveness and metastasis in patients suffering
from both PTC and HT could be used as a model in
studies investigating inflammation and cancer progres-




The study subjects were all patients treated from January,
2008, to December, 2010, at the Department of Head and
Neck Surgery at the Cancer Hospital of Fudan University
in Shanghai, China. All of the patients provided written
informed consent for their information to be stored in
the hospital database and used for research, and the study
was approved by the Ethical Committee of the Cancer
Hospital of Fudan University. The patients included in
the study met the following criteria: no previous thyroid
surgery, no PTC or benign thyroid nodule confirmed
by histopathology, and the availability of an adequate
medical history. A total of 6109 patients were included
in this study.
All patients with thyroid nodules underwent a thyroid
US examination in our hospital. In our hospital, we
selected patients with thyroid nodules for surgery based
on the suspicious features on the ultrasound images,
which were defined as micro-calcification, hypo-echoic,
increased nodular vascularity, infiltrative margin and
taller than wide on transverse view. A suspicious malig-
nant nodule was diagnosed when at least one of the
above images was present. Surgical operation was sug-
gested in patients with at least one suspicious malignant
nodule.
If more than one nodule were found under US, each
nodule in the whole thyroid gland was evaluated by one
clinical physician at the same time.
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lowed with serial US examinations every 3–6 months, es-
pecially in those with suspicious malignant nodule but
rejected the surgery suggestion considering the relative
good prognosis of PTMC and the potential risk of the op-
eration. Surgery was indicated during period of follow-up
when there was more than a 50% change in volume of
suspicious malignant nodules or presence of at least one
suspicious US feature mentioned above in other nodules.
In abstract, there were three criteria for our selecting
patients before surgery.
1. suspect ultrasound images, for example,
microcalcifications, hypoechoic, increased nodular
vascularity, infiltrative margins and taller than wide
on transverse view.
2. ultrasound images changed in the 3–6 months
follow-up
3. patients consent.
This was described in our previous paper [52]. For
patients with benign nodules, surgery only was done in
the nodule larger than 4 cm.Histopathology
Resected surgical specimens were fixed in 10% formalin
and cut at 5-um intervals. One to 3 representative sections
of the tumour and all suspicious lesions were submitted
for microscopy. All of the sections were fixed in formalin,
embedded in paraffin wax, and stained with haematoxylin
and eosin. HT was diagnosed by the presence of diffuse
lymphoplasmacytic infiltrations with germinal centres,
parenchymal atrophy with oncocytic changes, and variable
amounts of stromal fibrosis throughout the thyroid gland.
We examined and recorded any coexisting HT in all of
the patients included in the study.Serum thyroid function measurement
In our hospital, serum fT4, fT3, and TSH are mea-
sured by a chemiluminescent microparticle immunoassay
(Abbott Laboratories, Abbott Park, IL 60064, USA) that
has interassay coefficients of variations of less than 10%
over the ranges 2.63–5.70 pmol/litre, 9.01–19.05 pmol/
litre, and 0.35–4.94 μIU/mlitre.
Clinicopathologic variables assessed
The following variables were used in our study: gender,
age at diagnosis, maximal microscopic tumour size (the
largest diameter; for multifocal lesions, the maximal
microscopic tumour size of the largest lesion was used,
as outlined by the AJCC 7th edition), primary tumour in-
vasion and central lymph node status. Prophylactic
CLND was routinely performed when the results of thefrozen section indicated a malignant nodule. Invasion of
the primary tumour consisted of gross extrathyroidal ex-
tension and microscopic extrathyroidal extension, which
were assessed in the final pathology. The final pathology
decided the status of the lateral neck lymph nodes and if
there was central lymph node metastasis.
Statistical analysis
The results are expressed as the means ± standard de-
viation (SD). The statistical analysis was performed using
a Student’s T test or Mann–Whitney test or chi-square
test, when appropriate. ORs with 95% confidence inter-
vals (CIs) for the relationships between the variables and
PTC were calculated using binary logistic regression. A
p-value of less than 0.05 was considered statistically sig-
nificant. The statistical analyses were performed using
SPSS software, version 12.0 (SPSS, Chicago, IL, USA).
Additional file
Additional file 1: Figure S1. Hashimoto’s thyroiditis. Germinal centers
have formed in the gland and are associated with the smaller follicles
and the oxyphilic follicular cells. HE x 200. Figure S2. Papillary carcinoma
arises in the background OF Hashimoto’s thyroiditis. HE x 40. Figure S3.
PTC co-existence with HT. The carcinoma area (the lower portion) is next
to Hashimoto’s thyroiditis area(the upper portion). HE x 200. Figure S4.
PTC Distinct papillary structures are seen. A giant cell, common in
papillary carcinoma, is seen in this section. HE x 200.
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